A clinical trial to evaluate the safety and efficacy of CDR404 in cancer patients with solid tumors began at the end of May. CDR404 is a highly effective antibody developed by CDR-Life that stimulates the T-cells in the human body to selectively attack and destroy cancer cells.
“This first study is an important milestone for us,” emphasizes Dr Christian Leisner, CEO of CDR-Life. “We are thus taking the step from research to a highly effective and specific immunotherapy that can be used to treat cancer in the future.”
More information: